Proliferation of omnichannel commercial models has presented emerging biotechs with unique opportunities to improve their competitiveness. A suboptimal field sales rep channel and the acceleration of the digital sales model have leveled the playing field for all pharma companies. Emerging biotechs now have alternatives beyond licensing or being acquired to monetize their innovation. However, they need the right expertise for their journey from development through commercialization—one that is capital efficient and relevant to their unique needs. This panel discussion will explore the capabilities they need to realize their true revenue potential.
From this session, you will learn,
- What are the unique challenges emerging biotechs run into while commercializing their innovation?
- What capabilities do biotechs need to maximize and sustain returns on their investment?
- How can modern, data-driven practices help biotechs compete better?